Adma Biologics reported $44.44M in Current Liabilities for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Adamis Pharmaceuticals ADMP:US USD 8.87M 850.2K
Adma Biologics ADMA:US USD 44.44M 16.37M
Agile Therapeutics AGRX:US USD 11.65M 17.13M
Alnylam Pharmaceuticals ALNY:US USD 772.79M 115.11M
Dynavax Technologies DVAX:US USD 244.08M 101.12M
Minerva Neurosciences NERV:US USD 2.2M 1.21M
Novavax NVAX:US USD 1.67B 488.28M
Omeros OMER:US USD 39.51M 1.01M
Takeda 4502:JP JPY 2.39T 224.78B